Clinical Laboratory Improvement Advisory Committee (CLIAC), 43543-43544 [2017-19498]

Agencies

• Centers for Disease Control and Prevention
• DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 82, Number 179 (Monday, September 18, 2017)]
[Notices]
[Pages 43543-43544]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-19498]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Clinical Laboratory Improvement Advisory Committee (CLIAC)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: In accordance with the Federal Advisory Committee Act, the 
Centers for Disease Control and Prevention (CDC), announces the 
following meeting for the Clinical Laboratory Improvement Advisory 
Committee (CLIAC). This meeting is open to the public, limited only by 
the space available. The meeting room accommodates approximately 100 
people. The public is also welcome to view the meeting by webcast 
https://cdclabtraining.adobeconnect.com/cliac.

DATES: The meeting will be held on November 1, 2017, 8:30 a.m. to 5:00 
p.m., EDT and November 2, 2017, 8:30 a.m. to 12:00 p.m., EDT.

ADDRESSES: CDC, 2500 Century Center Boulevard, Rooms 1200/1201, 
Atlanta, Georgia 30345 and https://cdclabtraining.adobeconnect.com/cliac.

FOR FURTHER INFORMATION CONTACT: Nancy Anderson, MMSc, MT(ASCP), Chief, 
Laboratory Practice Standards Branch, Division of Laboratory Systems, 
Center for Surveillance, Epidemiology and Laboratory Services, Office 
of Public Health Scientific Services, Centers for Disease Control and 
Prevention, 1600 Clifton Road NE., Mailstop F-11, Atlanta, Georgia 
30329-4018, telephone (404) 498-2741; NAnderson@cdc.gov.

SUPPLEMENTARY INFORMATION: Purpose: This Committee is charged with 
providing scientific and technical advice and guidance to the Secretary 
of Health and Human Services (HHS); the Assistant Secretary for Health; 
the Director, Centers for Disease Control and Prevention; the 
Commissioner, Food and Drug Administration (FDA); and the 
Administrator, Centers for Medicare and Medicaid Services (CMS). The 
advice and guidance pertain to general issues related to improvement in 
clinical laboratory quality and laboratory medicine practice and 
specific questions related to possible revision of the Clinical 
Laboratory Improvement Amendment (CLIA) standards. Examples include 
providing guidance on studies designed to improve safety, 
effectiveness, efficiency, timeliness, equity, and patient-centeredness 
of laboratory services; revisions to the standards under which clinical 
laboratories are regulated; the impact of proposed revisions to the 
standards on medical and laboratory practice; and the modification of 
the standards and provision of non-regulatory guidelines to accommodate 
technological advances, such as new test methods, the electronic 
transmission of laboratory information, and mechanisms to improve the 
integration of public health and clinical laboratory practices.
    Matters To Be Considered: The agenda will include agency updates 
from CDC, Centers for Medicare and Medicaid Services (CMS), and The 
Food and Drug Administration (FDA). Presentations and discussions will 
focus on laboratory testing in the era of telemedicine; antibiotic 
resistance testing issues; culture independent diagnostic tests; and a 
report from the Institute of Medicine (IOM) CLIAC workgroup. Agenda 
items are subject to change as priorities dictate.
    All people attending the CLIAC meeting in-person are required to 
register for the meeting online at least 5 business days in advance for 
U.S. citizens and at least 30 business days in advance for 
international registrants. Register at: https://wwwn.cdc.gov/cliac/ cliac/. 
Register by scrolling down and clicking the ``Register for this 
Meeting'' button and completing all forms according to the instructions 
given. Please complete all the required fields before submitting your 
registration and submit no later than October 25, 2017 for U.S. 
registrants and September 19, 2017 for international registrants.
    It is the policy of CLIAC to accept written public comments and 
provide a brief period for oral public comments on agenda items. Public 
comment periods for each agenda item are scheduled immediately prior to 
the Committee discussion period for that item. In general, each 
individual or group requesting to make oral comments will be limited to 
a total time of five minutes (unless otherwise indicated). To assure 
adequate time is scheduled for public comments, speakers should notify 
the contact person below at least one week prior to the meeting date. 
For individuals or groups unable to attend the meeting, CLIAC accepts 
written comments until the date of the meeting (unless otherwise 
stated). However, it is requested that comments be submitted at least 
one week prior to the meeting date so that the comments may be made 
available to the Committee for their consideration and public 
distribution.

[[Page 43544]]

Written comments, one hard copy with original signature, should be 
provided to the contact person at the mailing or email address below, 
and will be included in the meeting's Summary Report.
    The CLIAC meeting materials will be made available to the Committee 
and the public in electronic format (PDF) on the internet instead of by 
printed copy. Check the CLIAC Web site on the day of the meeting for 
materials: https://wwwn.cdc.gov/cliac/.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities, 
for both the Centers for Disease Control and Prevention and the Agency 
for Toxic Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2017-19498 Filed 9-15-17; 8:45 am]
 BILLING CODE 4163-19-P